loading page

A SUCCESS STORY OF AN INFANTILE ANAPLASTIC LARGE CELL LYMPHOMA --A CASE REPORT.
  • +4
  • Sowmya J,
  • Nuthan Kumar,
  • Prakruthi Kaushik,
  • Arun Kumar,
  • Avinash T,
  • Arunakumari BS,
  • Appaji L
Sowmya J
Kidwai Memorial Institute of Oncology

Corresponding Author:[email protected]

Author Profile
Nuthan Kumar
Kidwai Memorial Institute of Oncology
Author Profile
Prakruthi Kaushik
Kidwai Memorial Institute of Oncology
Author Profile
Arun Kumar
Kidwai Memorial Institute of Oncology
Author Profile
Avinash T
Kidwai Memorial Institute of Oncology
Author Profile
Arunakumari BS
Kidwai Memorial Institute of Oncology
Author Profile
Appaji L
Kidwai Memorial Institute of Oncology
Author Profile

Abstract

Background: Anaplastic large cell lymphoma (ALCL) is an uncommon form of Non-Hodgkin Lymphoma (NHL) in younger patients, accounting for less than 15% of cases. The median age at presentation is 12 years and is exceedingly rare in infants. Various prognostic factors, risk stratification and novel treatment strategies have been studied in pediatric ALCL. There is no separate data available on the disease biology, treatment regimens and prognostic factors among infantile ALCL. Outcomes for infants with ALCL have been reported to be inferior to that of older children. The long-term Event Free Survival (EFS) in general among pediatric patients is approximately 70% regardless of the treatment approach. We report a case of an 8month old infant diagnosed with ALK positive ALCL with visceral organ involvement stratified as high risk and treated according to ALCL 99 protocol with excellent clinical response, on regular follow up and is disease free since 2years.
11 Jul 2023Submitted to Pediatric Blood & Cancer
11 Jul 2023Submission Checks Completed
11 Jul 2023Assigned to Editor
11 Jul 2023Review(s) Completed, Editorial Evaluation Pending
13 Jul 2023Editorial Decision: Revise Minor
29 Aug 2023Submission Checks Completed
29 Aug 2023Assigned to Editor
29 Aug 20231st Revision Received
29 Aug 2023Review(s) Completed, Editorial Evaluation Pending
30 Aug 2023Editorial Decision: Accept